BeiGene, Ltd. (NASDAQ:BGNE) COO Sells $900,630.00 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) COO Xiaobin Wu sold 4,500 shares of the firm’s stock in a transaction dated Thursday, September 19th. The shares were sold at an average price of $200.14, for a total value of $900,630.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, September 17th, Xiaobin Wu sold 500 shares of BeiGene stock. The stock was sold at an average price of $200.00, for a total value of $100,000.00.
• On Tuesday, September 3rd, Xiaobin Wu sold 5,556 shares of BeiGene stock. The shares were sold at an average price of $189.65, for a total value of $1,053,695.40.
• On Monday, June 24th, Xiaobin Wu sold 1,459 shares of BeiGene stock. The shares were sold at an average price of $159.79, for a total value of $233,133.61.

BeiGene Stock Up 1.7 %

NASDAQ BGNE opened at $201.99 on Friday. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $215.00. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.75 and a current ratio of 1.98. The stock has a market cap of $19.57 billion, a PE ratio of -26.68 and a beta of 0.61. The firm has a 50-day simple moving average of $182.24 and a 200 day simple moving average of $164.48.

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($1.15) earnings per share for the quarter, topping the consensus estimate of ($2.27) by $1.12. The company had revenue of $929.20 million for the quarter, compared to analyst estimates of $810.34 million. BeiGene had a negative return on equity of 14.93% and a negative net margin of 16.91%. BeiGene’s revenue for the quarter was up 56.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($3.64) EPS. On average, research analysts forecast that BeiGene, Ltd. will post -5.13 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on BGNE. Bank of America decreased their price objective on shares of BeiGene from $180.00 to $152.50 and set a “neutral” rating for the company in a report on Tuesday, July 9th. Citigroup upped their price target on shares of BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a report on Thursday, August 8th. JPMorgan Chase & Co. lifted their price objective on BeiGene from $194.00 to $200.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, JMP Securities started coverage on BeiGene in a research note on Wednesday. They set a “market outperform” rating and a $288.00 target price for the company. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, BeiGene presently has a consensus rating of “Moderate Buy” and an average target price of $241.21.

Institutional Investors Weigh In On BeiGene

Institutional investors and hedge funds have recently bought and sold shares of the business. Capital International Investors boosted its position in shares of BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock valued at $1,104,806,000 after acquiring an additional 727,556 shares in the last quarter. Point72 Asset Management L.P. bought a new position in BeiGene during the second quarter worth about $54,412,000. First Trust Advisors LP acquired a new stake in BeiGene during the fourth quarter valued at approximately $39,632,000. M&G Plc bought a new stake in shares of BeiGene in the 1st quarter valued at approximately $29,649,000. Finally, Goldman Sachs Group Inc. raised its holdings in shares of BeiGene by 175.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock worth $38,658,000 after buying an additional 136,458 shares in the last quarter. Institutional investors own 48.55% of the company’s stock.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.